

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

OS-RC-2

RRID:CVCL_1626

Type: Cell Line

Proper Citation

RRID:CVCL_1626

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1626

Proper Citation: RRID:CVCL_1626

Description: Cell line OS-RC-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Clear cell renal cell carcinoma

Defining Citation: [PMID:4008433](#), [PMID:14534724](#), [PMID:15604581](#), [PMID:20164919](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OS-RC-2

Synonyms: OSRC2, RC-2

Cross References: BTO:BTO_0002403, CLO:CLO_0050889, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:512, BioSample:SAMN03472222, BioSample:SAMN10987712, cancercellines:CVCL_1626, CCRID:1101HUM-PUMC000292, CCRID:3101HUMTCHu40, Cell_Model_Passport:SIDM00239, ChEMBL-Cells:ChEMBL3308274, ChEMBL-Targets:ChEMBL2366188, CLS:305086, Cosmic:909250, Cosmic-CLP:909250, DepMap:ACH-000159, EGA:EGAS00001000978, FANTOM5_SSTAR:10411-106B6, GDSC:909250, GEO:GSM1670310, IARC_TP53:21604, KCB:KCB 200779YJ,

LiGeA:CCLE_815, LINCS_LDP:LCL-1768, PharmacDB:OSRC2_1203_2019, PRIDE:PXD030304, Progenetix:CVCL_1626, PubChem_Cell_line:CVCL_1626, RCB:RCB0735, Wikidata:Q54936539

ID: CVCL_1626

Record Creation Time: 20220427T221400+0000

Record Last Update: 20260904T015339+0000

Ratings and Alerts

No rating or validation information has been found for OS-RC-2.

No alerts have been found for OS-RC-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 178 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. *Cell death & disease*, 17(1).

Shi H, et al. (2026) OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. *Cell death & disease*, 17(1).

Heritz JA, et al. (2026) Targeting and dissociating HIF2 α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. *Communications medicine*, 6(1), 91.

Yang T, et al. (2026) Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(42), e20237.

Sun S, et al. (2026) Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(42), e21975.

Zhang Q, et al. (2025) The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi. *Developmental cell*.

Jiang Q, et al. (2025) HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. *Cell*, 188(7), 1807.

Shirole NH, et al. (2025) Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. *Cancer discovery*, 15(7), 1484.

Luo Q, et al. (2025) PUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma. *Cell death & disease*, 16(1), 460.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Liu Y, et al. (2024) A1CF Binding to the p65 Interaction Site on NKRF Decreased IFN- γ Expression and p65 Phosphorylation (Ser536) in Renal Carcinoma Cells. *International journal of molecular sciences*, 25(7).

Yin L, et al. (2024) ACE Loss Drives Renal Cell Carcinoma Growth and Invasion by Modulating AKT-FOXO1. *Biologics : targets & therapy*, 18, 397.

Xu S, et al. (2024) Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. *EBioMedicine*, 104, 105162.

Cheng B, et al. (2023) Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. *Cell death discovery*, 9(1), 121.

Li T, et al. (2023) CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure. *Molecular cancer*, 22(1), 77.

Yuan Y, et al. (2023) FBXO30 functions as a tumor suppressor and an E3 ubiquitin ligase for hZIP1-mediated HIF-1 α degradation in renal cell carcinoma. *International journal of oncology*, 62(3).

Shen C, et al. (2023) Biochemical and clinical effects of RPS20 expression in renal clear cell carcinoma. *Oncology reports*, 49(1).

Wang Y, et al. (2023) A pan-cancer analysis of the expression and molecular mechanism of DHX9 in human cancers. *Frontiers in pharmacology*, 14, 1153067.

Ma S, et al. (2023) A novel gene signature related to oxidative stress predicts the prognosis in clear cell renal cell carcinoma. *PeerJ*, 11, e14784.

Zhang W, et al. (2023) piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination. *Experimental & molecular medicine*, 55(6), 1258.